Citation Impact
Citing Papers
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN
2013
Phthalimide conjugation as a strategy for in vivo target protein degradation
2015 Science
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
2008
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody responses in COVID-19 patients
2023 StandoutNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
2012
Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies
2017
Efficacy of Targeted 5-day Combined Parenteral and Intramammary Treatment of Clinical Mastitis Caused by Penicillin-Susceptible or Penicillin-Resistant Staphylococcus aureus
2003
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
2012
Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential
2004
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2012
Hepatocellular carcinoma
2018 Standout
Pharmacological Profile of the 5‐HT2C Receptor Agonist WAY‐163909; Therapeutic Potential in Multiple Indications
2006
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Tumor necrosis factor, cancer and anticancer therapy
2004
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
2010 Standout
Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages
2005 Standout
New thalidomide analogues derived through Sonogashira or Suzuki reactions and their TNF expression inhibition profiles
2009
Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma
2012
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
Juvenile idiopathic arthritis
2007 Standout
The olfactory bulbectomised rat as a model of depression
2005
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Multiple Myeloma
2004
Issues in T‐helper 1 development – resolved and unresolved
2004
The IKK NF-κB system: a treasure trove for drug development
2004
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
TH1 predominance is associated with improved survival in pediatric medulloblastoma patients
2011
Polyamines and cancer: implications for chemotherapy and chemoprevention
2013
Membrane vesicles as conveyors of immune responses
2009 Standout
Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD
2005
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
2005 StandoutNobel
Transforming growth factor-β induces development of the TH17 lineage
2006 StandoutNature
Nuclear factor-κB in cancer development and progression
2006 StandoutNature
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study
2004
Recent advances in MMP inhibitor design
2006
Lenalidomide (Revlimid®) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis
2009
Remodelling the extracellular matrix in development and disease
2014 Standout
Novel approaches in the therapy of metastatic renal cell carcinoma
2005
Next generation of immune checkpoint therapy in cancer: new developments and challenges
2018
Systemic amyloidosis
2015 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
2013
A Simple Enantioconvergent and Chemoenzymatic Synthesis of Optically Active α‐Substituted Amides
2011 StandoutNobel
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Thalidomide
2004
Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling
2017 StandoutNatureNobel
Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment
2005
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Signaling to NF-κB
2004 Standout
DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis
2020 StandoutNatureNobel
Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders
2008
Cancer-related inflammation
2008 StandoutNature
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
2009
Invited Review: The Role of Cow, Pathogen, and Treatment Regimen in the Therapeutic Success of Bovine Staphylococcus aureus Mastitis
2006 Standout
Anti-TNF-α therapies: the next generation
2003
Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents
2018
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
2017 Standout
The thalidomide saga
2007
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
2007
Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells
2006
Recent advances in Sonogashira reactions
2011 Standout
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Efficient Asymmetric Synthesis of Novel 4-Substituted and Configurationally Stable Analogues of Thalidomide
2006
Regulatory T Cells and Human Disease
2020 StandoutNobel
Self-disproportionation of enantiomers of thalidomide and its fluorinated analogue via gravity-driven achiral chromatography: mechanistic rationale and implications
2014
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Marine Indole Alkaloids: Potential New Drug Leads for the Control of Depression and Anxiety
2010 Standout
Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
2013
Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
2010
Targeting the bone marrow microenvironment in multiple myeloma
2014
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Suppression of Melanoma Growth and Metastasis by DNA Vaccination Using an Ultrasound-Responsive and Mannose-Modified Gene Carrier
2011
Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
2008
Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction
2005 Standout
Spermidine in health and disease
2018 StandoutScience
Structure and functional properties of Norrin mimic Wnt for signalling with Frizzled4, Lrp5/6, and proteoglycan
2015
Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence
2014
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Siglec-G–CD24 axis controls the severity of graft-versus-host disease in mice
2014
Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm
2009
Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3− precursors
2007 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Ribosomopathies: human disorders of ribosome dysfunction
2010
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
2011
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
2017
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
2009
Physiology of Microglia
2011 Standout
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
2006
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of Keith Dredge being referenced
PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer
2013
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
2003
PI-88 and Novel Heparan Sulfate Mimetics Inhibit Angiogenesis
2007
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation
2012
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
2011
Efficacy of intramammary treatment with procaine penicillin G vs. procaine penicillin G plus neomycin in bovine clinical mastitis caused by penicillin‐susceptible, gram‐positive bacteria – a double blind field study
2003
Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression
1999
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
2008
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
2005
Thalidomide analogs as emerging anti-cancer drugs
2003
The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer
2009
Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1β and tumor necrosis factor-α secretion following an in vivo lipopolysaccharide challenge in rats
1999
Recent developments in antiangiogenic therapy
2002
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
2002
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers
2004
Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy
2002
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues
2013
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity
2002
Thalidomide and its analogues have distinct and opposing effects on TNF-αand TNFR2 during co-stimulation of both CD4+ and CD8+ T cells
2002
AE-941 (AEterna).
2004
Angiogenesis inhibitors in cancer therapy.
2003
The evolution of thalidomide and its IMiD derivatives as anticancer agents
2004
Synthesis and Biological Evaluation of Polysulfated Oligosaccharide Glycosides as Inhibitors of Angiogenesis and Tumor Growth
2010
An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.
2017
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine
2014
Immunological Effects of Thalidomide and Its Chemical and Functional Analogs
2002